Options
Identification of a mutation in LARS as a novel cause of infantile hepatopathy
File(s)
File | Description | Size | Format | |
---|---|---|---|---|
Casey_LARS_2012.pdf | 1.18 MB |
Date Issued
July 2012
Date Available
07T11:03:03Z August 2014
Abstract
Infantile hepatopathies are life-threatening liver disorders that manifest in the first few months of life. We report on a consanguineous Irish Traveller family that includes six individuals presenting with acute liver failure in the first few months of life. Additional symptoms include anaemia, renal tubulopathy, developmental delay, seizures, failure to thrive and deterioration of liver function with minor illness. The multisystem manifestations suggested a possible mitochondrial basis to the disorder. However, known causes of childhood liver failure and mitochondrial disease were excluded in this family by biochemical, metabolic and genetic analyses. We aimed to identify the underlying risk gene using homozygosity mapping and whole exome sequencing. SNP homozygosity mapping identified a candidate locus at 5q31.3–q33.1. Whole exome sequencing identified 1 novel homozygous missense mutation within the 5q31.3–q33.1 candidate region that segregated with the hepatopathy. The candidate mutation is located in the LARS gene which encodes a cytoplasmic leucyl-tRNA synthetase enzyme responsible for exclusively attaching leucine to its cognate tRNA during protein translation. Knock-down of LARS in HEK293 cells did not impact on mitochondrial function even when the cells were put under physiological stress. The molecular studies confirm the findings of the patients' biochemical and genetic analyses which show that the hepatopathy is not a mitochondrial-based dysfunction problem, despite clinical appearances. This study highlights the clinical utility of homozygosity mapping and exome sequencing in diagnosing recessive liver disorders. It reports mutation of a cytoplasmic aminoacyl-tRNA synthetase enzyme as a possible novel cause of infantile hepatopathy and underscores the need to consider mutations in LARS in patients with liver disease and multisystem presentations.
Sponsorship
Health Research Board
Irish Research Council for Science, Engineering and Technology
Science Foundation Ireland
Other Sponsorship
Children's Fund for Health, The Fundraising Office for Temple Street Children's University Hospital
Medical Research Charities Group
National Children's Research Centre
Type of Material
Journal Article
Publisher
Elsevier
Journal
Molecular Genetics and Metabolism
Volume
106
Issue
3
Start Page
351
End Page
358
Copyright (Published Version)
2012 Elsevier
Language
English
Status of Item
Peer reviewed
This item is made available under a Creative Commons License
Owning collection
Scopus© citations
65
Acquisition Date
Mar 20, 2023
Mar 20, 2023
Views
2813
Last Week
1
1
Last Month
5
5
Acquisition Date
Mar 20, 2023
Mar 20, 2023
Downloads
636
Last Month
18
18
Acquisition Date
Mar 20, 2023
Mar 20, 2023